People are filing lawsuits against Pfizer after experiencing severe complications from taking Oxbryta (voxelotor), a drug intended to treat sickle cell disease (SCD). On September 25, 2024, the drug was voluntarily withdrawn from global markets after data revealed it increased the risk of vaso-occlusive crises (VOCs) and death conditions it was meant to prevent.
Lawsuits allege that the manufacturer failed to validly warn patients about these dangers. Injured patients and families are now seeking compensation for medical costs, pain and suffering, and wrongful death associated with the drug.
Oxbryta (voxelotor) was a prescription medication capable of treating sickle cell disease (SCD) by inhibiting hemoglobin S polymerization. It was designed to target the root cause of sickling cells to prevent complications. However, post-marketing studies showed that instead of helping, widespread use was associated with worse outcomes, including higher rates of VOCs and mortality.
If you or a loved one suffered severe injury or death after taking Oxbryta, you may be entitled to significant compensation.
You typically qualify to file a claim if you:
We use cookies to analyze website traffic and optimize your website experience. By accepting our use of cookies, your data will be aggregated with all other user data.